Related Experiment Videos
The interaction of tilorone and RMI 9563DA with the complement system
International Journal of Immunopharmacology
|January 1, 1982
Summary
RMI 9563DA and tilorone inhibit complement pathways in vitro, but not in vivo. Their anti-inflammatory effects are not mediated by complement inhibition, suggesting alternative mechanisms like interferon induction for tilorone.
Area of Science:
- Immunology
- Pharmacology
Background:
- The complement system is a crucial part of innate immunity.
- Understanding the mechanisms of anti-inflammatory drugs is essential for therapeutic development.
Purpose of the Study:
- To investigate the in vitro and in vivo effects of RMI 9563DA and tilorone on the complement system.
- To determine if complement inhibition is the mechanism underlying the anti-inflammatory activity of these compounds.
Main Methods:
- In vitro classical complement pathway inhibition assays using rat serum (diluted and undiluted).
- In vivo complement activity assessment in rats after administration of RMI 9563DA and tilorone.
- Evaluation of serum hemolytic complement activity at 24 hours post-administration.
Main Results:
- RMI 9563DA demonstrated in vitro complement inhibition (IC50 of 51 µg/ml in diluted and 750 µg/ml in undiluted serum).
- Tilorone showed less in vitro activity and no inhibition in undiluted serum.
- No complement inhibition was observed in vivo even at a near-lethal dose of RMI 9563DA.
- Both compounds increased serum hemolytic complement activity 24 hours post-administration, attributed to local irritancy for RMI 9563DA and potentially specific complement synthesis effects for tilorone.
Conclusions:
- Complement inhibition is not the mechanism of anti-inflammatory action for RMI 9563DA or tilorone.
- Tilorone may influence complement synthesis, possibly linked to interferon induction.
- Further research is needed to elucidate the precise anti-inflammatory mechanisms of these compounds.